Search
ligelizumab
Indications:
- chronic spontaneous urticaria*
* large beneficial effect in antihistamine-refractory chronic spontaneous urticaria [3]
Dosage:
- 72, 120 or 240 mg SQ every 4 weeks [3]
Mechanism of action:
- anti-IgE antibody
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
pharmaceutical monoclonal antibody
References
- Maurer M, Gimenez-Arnau, Sussman G et al.
Ligelizumab for chronic spontaneous urticaria.
N Engl J Med 2019 Oct 3; 381:1321
PMID: 31577874
https://www.nejm.org/doi/10.1056/NEJMoa1900408
- Bowser AD
New Hope for Chronic Spontaneous Urticaria?
Ligelizumab and other drugs could offer relief for patients with
'the devil's itch'.
MedPage Today. AAD Reading Room 11.05.2019
https://www.medpagetoday.com/reading-room/aad/general-dermatology/83142
- Nochaiwong S, Chuamanochan M, Ruengorn C et al
Evaluation of Pharmacologic Treatments for H1 Antihistamine-Refractory
Chronic Spontaneous Urticaria. A Systematic Review and Network Meta-analysis.
JAMA Dermatol. Published online August 25, 2021
PMID: 34431983
https://jamanetwork.com/journals/jamadermatology/fullarticle/2783033